Previously Untreated Metastatic

2-yr RELATIVITY-047: nivolumab + relatlimab in previously untreated metastatic/unresectable melanoma

Managing Untreated, Metastatic Renal Cell Carcinoma

Immunotherapy Now and Future for Metastatic Renal Cell Carcinoma Jianjun Gao, MD, PhD

The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC

Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC

The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

Dr. Kim on the KEYNOTE-189 Trial in Metastatic NSCLC

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference

University of California Television (UCTV)

How long can you expect to live with metastatic breast cancer?

You and Breast Cancer

The IMpassion130 Study in Metastatic TNBC

Targeted Oncology

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

FDA Ðại afatinib signs to previously untreated, metastatic NSCLC other EGFR mutation not subject

Love Later Life

DANUBE: PD-L1 as a predictor of survival in patients with mUC

DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC

Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC